What to Expect From Biogen’s Q3 2025 Earnings Report

Valued at a market cap of $22.1 billion, Biogen Inc. (BIIB) is a top biotechnology company. Headquartered in Cambridge, Massachusetts, it specializes in the discovery, development, and delivery of therapies for neurological, neurodegenerative, and rare diseases. Founded in 1978, Biogen has built a strong presence in neuroscience, focusing on addressing unmet medical needs in conditions such as multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease. The biotech titan is scheduled t ...